News
Hazardous Drug Compounding: The Safety Standards Behind Every Prescription
Quick Answer
Hazardous drug compounding is the careful preparation of medications that can harm the people who handle them, such as chemotherapy or hormone treatments. It follows strict safety standards that control the air, equipment, and protective gear used during...
Business & Industry
Hengrui Pharma and Novo Nordisk Sign Licensing Deal for Oral GLP-1/GIP Dual Agonist HRS-1596
Hengrui Pharma has entered into a licensing agreement with Novo Nordisk for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist with potential for once-weekly oral dosing, in a deal valued at...
Business & Industry
US Details Eligibility for Section 232 Specialty Pharmaceutical Tariff Exemptions
The Trump administration has released detailed guidance regarding specialty pharmaceutical tariff exemptions for products including orphan treatments, nuclear medicines, cell and gene therapies, and antibody-drug conjugates (ADCs). Effective September 29, 2026, these rules allow specific drug classes to enter...
News
Top Small Molecule API Partners for 2026
Choosing a small-molecule API manufacturing partner affects cost and timelines. It also affects regulatory outcomes for years after the contract is signed.
The stakes are rising alongside the market itself. The global small molecule API CDMO market reached an estimated...
Business & Industry
Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal
Roche-owned Genentech has entered into a major collaboration with Earendil Labs to discover and develop bispecific antibodies targeting oncology, in a deal valued at up to $1.5 billion.
Deal Structure and Financial Terms
Under the terms of the agreement, Earendil will...
Business & Industry
AbbVie and Iambic Partner to Accelerate AI Drug Discovery in Immunology, Neuroscience and Oncology
AbbVie and Iambic have entered into a multiyear collaboration focused on AI drug discovery across three major therapeutic areas — immunology, neuroscience, and oncology. The partnership brings together Iambic's molecular superintelligence platform and AbbVie's established drug discovery expertise, with...
Business & Industry
Treatment for Rare Disease cALD Approved by European Commission
Neuraxpharm and Minoryx Therapeutics have secured European Commission approval for Nezglyal (leriglitazone), making it the first approved drug therapy for rare disease cALD — cerebral adrenoleukodystrophy — in the European Union, with a commercial launch expected before the end...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read